Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal

This article was originally published in PharmAsia News

Executive Summary

NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
Advertisement

Related Content

China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
Roche Looks To Fuel Early-stage Partnerships In China While Shunning Branded Generics
Roche Looks To Fuel Early-stage Partnerships In China While Shunning Branded Generics
China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
China's Essential Drug Prices Less Severe Than Expected; Some Prices See Increases
Advertisement
UsernamePublicRestriction

Register

SC078807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel